NorthWest Biotherapeutics Inc (NWBO)

[photonic5]

Good points. High risk prostate cancer is an unmet need, but prostate cancer doesn’t represent orphan status disease like GBM. Low and medium risk prostate cancer have decent treatment options. I think what I was trying to say is that the acute need for prostate cancer treatment options doesn’t match the acute need for GBM treatment options, where finding treatment improvements can be measured in weeks.

If the DCVAX modality is shown to work in GBM, the sky is the limit on where else it may work. I think it was a good place to start the prove out of this technology and there probably are reasons that nobody jumped on board with the prostate product.